Canada - English - Health Canada

sanofi pasteur limited - meningococcal polysaccharide antigen group a; meningococcal polysaccharide antigen group c; meningococcal polysaccharide antigen group y; meningococcal polysaccharide antigen group w-135 - kit - 50mcg; 50mcg; 50mcg; 50mcg - meningococcal polysaccharide antigen group a 50mcg; meningococcal polysaccharide antigen group c 50mcg; meningococcal polysaccharide antigen group y 50mcg; meningococcal polysaccharide antigen group w-135 50mcg - vaccines

Canada - English - Health Canada

pfizer canada ulc - meningococcal polysaccharide antigen group a; meningococcal polysaccharide antigen group c; meningococcal polysaccharide antigen group w-135; meningococcal polysaccharide antigen group y; tetanus toxoid - kit - 5mcg; 5mcg; 5mcg; 5mcg; 44mcg - meningococcal polysaccharide antigen group a 5mcg; meningococcal polysaccharide antigen group c 5mcg; meningococcal polysaccharide antigen group w-135 5mcg; meningococcal polysaccharide antigen group y 5mcg; tetanus toxoid 44mcg - vaccines

Israel - English - Ministry of Health

pfizer pharmaceuticals israel ltd - pneumococcal polysaccharide serotype 1; pneumococcal polysaccharide serotype 14; pneumococcal polysaccharide serotype 18c; pneumococcal polysaccharide serotype 19 f; pneumococcal polysaccharide serotype 19a; pneumococcal polysaccharide serotype 23f; pneumococcal polysaccharide serotype 3; pneumococcal polysaccharide serotype 4; pneumococcal polysaccharide serotype 5; pneumococcal polysaccharide serotype 6a; pneumococcal polysaccharide serotype 6b; pneumococcal polysaccharide serotype 7f; pneumococcal polysaccharide serotype 9v - suspension for injection - pneumococcal polysaccharide serotype 23f 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 19 f 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 14 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 9v 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 7f 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 6b 4.4 mcg / 0.5 ml; pneumococcal polysaccharide serotype 5 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 4 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 1 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 3 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 6a 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 18c 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 19a 2.2 mcg / 0.5 ml - pneumococcus, purified polysaccharides antigen conjugated - pneumococcus, purified polysaccharides antigen conjugated - active immunisation for the prevention of invasive disease, pneumonia and acute otitis media caused by streptococcus pneumoniae in infants, children and adolescents from 6 weeks to 17 years of age.active immunisation for the prevention of invasive disease and pneumonia caused by streptococcus pneumoniae in adults ≥18 years of age and the elderly

Ireland - English - HPRA (Health Products Regulatory Authority)

gsk vaccines s.r.l. - meningococcal group c oligosaccharide; corynebacterium diphtheriae crm197 protein - suspension for injection - 10 - meningococcal vaccines; other meningococcal polyvalent purified polysaccharides antigen

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

sanofi-aventis (malaysia) sdn. bhd. - purified meningococcal polysaccharide group a; purified meningococcal polysaccharide group c; purified meningococcal polysaccharide group y; purified meningococcal polysaccharide group w135 -

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - meningococcal polysaccharide - group w135; meningococcal polysaccharide - group a; meningococcal polysaccharide - group y; meningococcal polysaccharide - group c -

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - pneumococcal polysaccharide serotype 1 1ug (conjugated with nthi protein d);  ;  ; pneumococcal polysaccharide serotype 14 1ug (conjugated with nthi protein d);  ;  ; pneumococcal polysaccharide serotype 18c 3ug (conjugated with tetanus toxoid);  ;  ; pneumococcal polysaccharide serotype 19f 3ug (conjugated with diptheria toxoid);  ;  ; pneumococcal polysaccharide serotype 23f 1ug (conjugated with nthi protein d);  ;  ; pneumococcal polysaccharide serotype 4 3ug (conjugated with nthi protein d);  ;  ; pneumococcal polysaccharide serotype 5 1ug (conjugated with nthi protein d);  ;  ; pneumococcal polysaccharide serotype 6b 1ug (conjugated with nthi protein d);  ;  ; pneumococcal polysaccharide serotype 7f 1ug (conjugated with nthi protein d);  ;  ; pneumococcal polysaccharide serotype 9v 1ug (conjugated with nthi protein d);  ;   - suspension for injection - active: pneumococcal polysaccharide serotype 1 1ug (conjugated with nthi protein d)     pneumococcal polysaccharide serotype 14 1ug (conjugated with nthi protein d)     pneumococcal polysaccharide serotype 18c 3ug (conjugated with tetanus toxoid)     pneumococcal polysaccharide serotype 19f 3ug (conjugated with diptheria toxoid)     pneumococcal polysaccharide serotype 23f 1ug (conjugated with nthi protein d)     pneumococcal polysaccharide serotype 4 3ug (conjugated with nthi protein d)     pneumococcal polysaccharide serotype 5 1ug (conjugated with nthi protein d)     pneumococcal polysaccharide serotype 6b 1ug (conjugated with nthi protein d)     pneumococcal polysaccharide serotype 7f 1ug (conjugated with nthi protein d)     pneumococcal polysaccharide serotype 9v 1ug (conjugated with nthi protein d)     excipient: aluminium phosphate diphtheria toxoid, adsorbed haemophilus influenzae protein d sodium chloride tetanus toxoid water for injection - synflorix is indicated for the active immunisation of infants and children from the age of 6 weeks up to 5 years against disease caused by streptococcus pneumoniae vaccine serotypes 1, 4, 5, 6b, 7f, 9v, 14, 18c, 19f, 23f and cross-reactive serotype 19a (including invasive disease, pneumonia and acute otitis media).

Israel - English - Ministry of Health

pfizer pharmaceuticals israel ltd - neisseria meningitidis group a polysaccharide; neisseria meningitidis group c polysaccharide; neisseria meningitidis group w - 135 polysaccharide; neisseria meningitidis group y polysaccharide - powder and solvent for solution for injection - neisseria meningitidis group y polysaccharide 5 mcg; neisseria meningitidis group w - 135 polysaccharide 5 mcg; neisseria meningitidis group c polysaccharide 5 mcg; neisseria meningitidis group a polysaccharide 5 mcg - other meningococcal monovalent purified polysaccharides antigen - other meningococcal monovalent purified polysaccharides antigen - nimenrix is indicated for active immunisation of individuals from the age of 6 weeks against invasive meningococcal diseases caused by neisseria meningitidis group a, c, w-135 and y.

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi pasteur msd ltd - vi polysaccharide of salmonella typhi, hepatit a virus antigen - suspension for injection - bacterial and viral vaccines, combined

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi - hepatitis a virus (gbm strain) inactivated; salmonella typhi (ty2 strain) vi capsular polysaccharide - suspension for injection